Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule

@inproceedings{Parasrampuria2015EvaluationOR,
  title={Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule},
  author={Dolly A. Parasrampuria and Taro Kanamaru and Alyson L Connor and Ian Wilding and Ken-ichiro Ogata and Yoshimasa Shimoto and Satoshi Kunitada},
  booktitle={Journal of clinical pharmacology},
  year={2015}
}
Two studies in healthy subjects assessed the absorption of edoxaban when delivered to specific locations within the gastrointestinal tract using Enterion capsules. In study 1 (single-dose, 4-way crossover), 8 participants received edoxaban 60 mg as immediate-release (IR) tablets (treatment A), as powder formulation delivered to the distal small bowel (treatment B) or ascending colon (treatment C), or as an aqueous suspension delivered to the ascending colon (treatment D). In study 2 (single… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-9 OF 9 REFERENCES

Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.

  • Drug metabolism and disposition: the biological fate of chemicals
  • 2012
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition.

  • Drug metabolism and disposition: the biological fate of chemicals
  • 2014
VIEW 2 EXCERPTS

The effect of rifampin on the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban in healthy subjects

J Mendell, S Chen, L He, M Desai, DA. Parasrampuria
  • J Thromb Haemost
  • 2014
VIEW 1 EXCERPT